TRDA
Entrada Therapeutics, Inc.Healthcare·Biotechnology
$7.07
$274M market cap
Revenue
$2.2M
Free Cash Flow
$-73.7M
Rev Growth
+0.0%
FCF Margin
-3391.7%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the tre
2-Year Price History
$6.56-57.6%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.9 | -41.5 | -42.3 | -39.7 | -41.7 | -41.7 | -0.0 | 254.9 | 49.8 | 41.8 | -150.5% | -- | -- |
| Act | 2025-Q4 | 1.3 | -41.9 | -42.2 | -39.2 | -32.2 | -32.0 | -0.2 | 295.7 | 50.9 | 41.4 | -112.3% | -- | -- |
Valuation & Metrics
Market Stats
Price$7.07
Market Cap$274M
Enterprise Value$69M
P/S Ratio126.3x
P/FCF--
EV/FCF--
FCF Margin (TTM)-3391.7%
FCF Yield-26.9%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$2.2M
Net Income$-78.9M
Free Cash Flow$-73.7M
Revenue Growth (YoY)+0.0%
EBITDA Margin-3834.2%
Net Margin-3628.4%
FCF Margin-3391.7%
CapEx % of Revenue11.5%
SBC % of Revenue200.5%
ROIC-131.4%
WC Change % Rev29.5%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.0M
Days to Cover5.5
Change (vs Prior)+17.1%
Need at least 2 settlement dates for chart
Employees
Headcount183
Revenue / Employee$11,880
Gross Profit / Employee$2,639
Cash Runway
41.5months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
101.0%(+8.7% YoY)
105 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
29.7%(+10.2% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.2% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $64.0M | $11.11 | +$0 | +$2.6M | -0.4% | $16.13B |
| 5AM Venture Management, LLC | $51.2M | $12.18 | +$0 | −$4.4M | +1.3% | $360M |
| BlackRock, Inc.Passive | $29.8M | $15.25 | +$2.7M | +$4.6M | -0.2% | $5.69T |
| TCG Crossover Management, LLC | $28.9M | $10.55 | +$2.5M | +$21.5M | +4.7% | $3.50B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $15.9M | $12.62 | +$15.9M | +$15.9M | — | $4.04T |
| WELLINGTON MANAGEMENT GROUP LLP | $13.1M | $11.45 | −$126K | −$234K | -0.3% | $533.98B |
| StepStone Group LP | $9.6M | $15.76 | +$0 | +$0 | -5.6% | $207M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $8.4M | $14.04 | +$346K | +$988K | +2.3% | $1.61T |
| STATE STREET CORPPassive | $6.7M | $14.92 | +$316K | +$497K | -0.2% | $2.89T |
| PRICE T ROWE ASSOCIATES INC /MD/ | $6.6M | $14.70 | +$2.5M | −$27.9M | -0.2% | $864.93B |
| MILLENNIUM MANAGEMENT LLC | $6.6M | $8.33 | +$273K | +$6.6M | -0.5% | $127.40B |
| Jones Hill Capital LP | $4.7M | $12.62 | +$4.7M | +$4.7M | — | $466M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $4.2M | $11.74 | −$364K | +$1.6M | +0.4% | $23.79B |
| ACADIAN ASSET MANAGEMENT LLC | $4.2M | $8.12 | +$282K | +$3.9M | -0.5% | $70.48B |
| DIMENSIONAL FUND ADVISORS LPPassive | $4.1M | $12.46 | +$645K | −$33K | -0.4% | $480.92B |
| NORTHERN TRUST CORPPassive | $3.0M | $15.71 | +$110K | −$949K | -0.2% | $755.34B |
| VANGUARD PORTFOLIO MANAGEMENT LLCPassive | $2.8M | $12.62 | +$2.8M | +$2.8M | — | $1.91T |
| Woodline Partners LP | $2.7M | $11.08 | +$932K | +$2.7M | -0.1% | $26.43B |
| CITADEL ADVISORS LLC | $2.7M | $8.24 | −$981K | +$2.5M | -0.4% | $138.22B |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2.7M | $14.17 | −$82K | +$278K | +0.7% | $645.81B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+0.33%
avg per quarter
Holders (ex-self)
+0.44%
excl. this stock
Buyers (this Q)
+1.02%
64 buyers · $0.07B in
Sellers (this Q)
-1.37%
34 sellers · $0.00B out
alpha coverage: 92% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-14.6%
how holders react when this stock falls
On quiet Qs
-0.5%
−10% to +10% baseline
On rallies (+10%+)
-2.9%
how they react when this stock rises
Holders' portfolio flow this Q
+0.2%
inflows — adds are organic
Sellers' portfolio flow this Q
+29.5%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-3.6%
Holder mid (any stock)
-3.4%
Holder rally (any stock)
-4.7%
Biggest decreases this quarter
ALGERT GLOBAL LLCexited−$1.3MSPHERA FUNDS MANAGEMENT LTD.exited−$1.1MCITADEL ADVISORS LLC−$981Kα-0.4RENAISSANCE TECHNOLOGIES LLC−$638Kα+1.2JACOBS LEVY EQUITY MANAGEMENT, INC−$364Kα+0.4LOS ANGELES CAPITAL MANAGEMENT & EQUITY RESEARCH INCexited−$317KPoint72 Asset Management, L.P.exited−$225KBALYASNY ASSET MANAGEMENT LLCexited−$144KWalleye Capital LLCexited−$139KMagnetar Financial LLCexited−$137K
New buyers this quarter
Top-5 holders · 59.0%
BAKER BROS. ADVISORS LP--
5AM Venture Management, LLC--
BlackRock, Inc.--
TCG Crossover Management, LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
BAKER BROS. ADVISORS LP5.1M5AM Venture Management, LLC4.1MMPM ASSET MANAGEMENT LLC—WELLINGTON MANAGEMENT GROUP LLP1.0MPRICE T ROWE ASSOCIATES INC /MD/526KJANUS HENDERSON GROUP PLC—Redmile Group, LLC—TCG Crossover Management, LLC2.3MFMR LLC17KStepStone Group LP761K
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$10.004140.0%
Last Year (4 analysts)$16.0012630.0%
Current Price$7.07
Analyst Ratings
3
2
Buy: 3Hold: 2Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$29K
1 txn · 1 insider · 5,000 sh
Sells ($, 12mo)
$1.26M
9 txns · 3 insiders · 91,792 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$1.61M
4 txns · 1 insider · 206,911 sh
Sells ($, 12mo)
$5.66M
10 txns · 2 insiders · 704,000 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | BUY | Zeiher Bernhardt G | director | 5,000 | $5.86 | $29K | $29K |
| 2026-05-04 | SELL | Dowden Nathan J | officer: President & COO | 15,000 | $15.33 | $230K | $3.04M |
| 2026-05-04 | SELL | Sethuraman Natarajan | officer: President, Research & Develop. | 25,907 | $15.39 | $399K | $3.33M |
| 2026-04-01 | SELL | WENTWORTH KORY JAMES | officer: Chief Financial Officer | 2,500 | $12.95 | $32K | $1.54M |
| 2026-03-10 | SELL | Dowden Nathan J | officer: President & COO | 11,894 | $13.05 | $155K | $2.59M |
| 2026-03-10 | SELL | WENTWORTH KORY JAMES | officer: Chief Financial Officer | 11,388 | $13.02 | $148K | $1.58M |
| 2026-03-09 | SELL | Dowden Nathan J | officer: President & COO | 3,116 | $13.02 | $41K | $2.74M |
| 2026-03-09 | SELL | WENTWORTH KORY JAMES | officer: Chief Financial Officer | 5,089 | $13.00 | $66K | $1.73M |
| 2026-03-04 | SELL | WENTWORTH KORY JAMES | officer: Chief Financial Officer | 7,988 | $12.25 | $98K | $1.69M |
| 2025-11-21 | SELL | WENTWORTH KORY JAMES | officer: Chief Financial Officer | 8,910 | $9.98 | $89K | $1.10M |
| 2025-11-20 | BUY | BAKER BROS. ADVISORS LP | 10 percent owner | 28,867 | $9.07 | $262K | $42.55M |
| 2025-11-14 | SELL | PARMAR KUSH | director, 10 percent owner: | 200,000 | $8.80 | $1.76M | $26.07M |
| 2025-11-14 | SELL | 5AM Ventures V, L.P. | 10 percent owner | 200,000 | $8.80 | $1.76M | $26.07M |
| 2025-11-12 | BUY | BAKER BROS. ADVISORS LP | 10 percent owner | 100,736 | $7.76 | $782K | $36.20M |
| 2025-11-11 | BUY | BAKER BROS. ADVISORS LP | 10 percent owner | 46,434 | $7.50 | $348K | $34.29M |
| 2025-11-10 | BUY | BAKER BROS. ADVISORS LP | 10 percent owner | 30,874 | $7.21 | $223K | $32.68M |
| 2025-07-09 | SELL | 5AM Ventures V, L.P. | 10 percent owner | 27,000 | $7.50 | $203K | $8.20M |
| 2025-07-09 | SELL | PARMAR KUSH | director, 10 percent owner: | 27,000 | $7.50 | $203K | $8.20M |
| 2025-07-01 | SELL | 5AM Ventures V, L.P. | 10 percent owner | 25,000 | $7.12 | $178K | $7.84M |
| 2025-07-01 | SELL | PARMAR KUSH | director, 10 percent owner: | 25,000 | $7.12 | $178K | $7.84M |
Order Flow (FINRA, ~3w lag)
10.1%retail-0.7pp
16.8%dark-0.4pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Entrada Therapeutics: The Vertex Mirage and the 20% Reckoning
Overall Risk
6/10
Fraud
3/10
Dilution
7/10
Insolvency
4/10
Earnings Overstated
5/10
Hidden Liabilities
2/10
Legal
2/10
Audit Warnings
2/10
Hidden Upside
6/10
Contextually Acceptable
7/10